A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2018
At a glance
- Drugs CRS 207 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aduro BioTech
- 31 Aug 2018 Biomarkers information updated
- 12 Dec 2017 Status changed from active, no longer recruiting to discontinued, as reported in an Aduro BioTech media release.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.